THERADAPTIVE ANNOUNCES FIRST PATIENT TREATED IN OASIS CLINICAL TRIAL OF ...

Theradaptive's Phase I/II OASIS Trial treats first patient with OsteoAdapt SP in spinal fusion, aiming to improve safety and effectiveness over autologous bone graft. OsteoAdapt SP, containing next-gen protein AMP2, targets degenerative disc disease and offers potential benefits in various medical fields.